AURA
Aura Biosciences, Inc.
Biotechnology
Market Cap$412M
5Y Perf.-56.7%
Build Your Comparison
Side-by-side financial analysisAURA
IMVT
REGN
OCUL
Try popular comparisons:
Stock Comparison
AURA vs IMVT vs REGN vs OCUL
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.90B
5Y Perf.+318.2%
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$63.60B
5Y Perf.-4.3%
OCUL
Ocular Therapeutix, Inc.
Biotechnology
Market Cap$1.96B
5Y Perf.+34.6%
AURA vs IMVT vs REGN vs OCUL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  AURA |  IMVT |  REGN |  OCUL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $412M | $6.90B | $63.60B | $1.96B |
| Revenue (TTM) | $0.00 | $0.00 | $14.92B | $52M |
| Net Income (TTM) | $-112M | $-506M | $4.42B | $-290M |
| Gross Margin | — | — | 84.5% | 87.2% |
| Operating Margin | — | — | 24.3% | -5.8% |
| Forward P/E | — | — | 13.2x | — |
| Total Debt | $17M | $72K | $2.71B | $80M |
| Cash & Equiv. | $60M | $902M | $3.12B | $737M |
AURA vs IMVT vs REGN vs OCUL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AURA
IMVT
REGN
OCUL
| Stock | Oct 21 | Jun 26 | Return |
|---|---|---|---|
| Aura Biosciences, I… (AURA) | 100 | 43.3 | -56.7% |
| Immunovant, Inc. (IMVT) | 100 | 418.2 | +318.2% |
| Regeneron Pharmaceu… (REGN) | 100 | 95.7 | -4.3% |
| Ocular Therapeutix,… (OCUL) | 100 | 134.6 | +34.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AURA vs IMVT vs REGN vs OCUL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Immunovant, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇REGN emerged as the overall leader. Track its performance:
AURA
Aura Biosciences, Inc.
The Specific-Use Pick
AURA plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 237.9% 10Y total return vs REGN's 68.2%
- +110.9% vs AURA's -3.9%
Best for: long-term compounding
REGN
Regeneron Pharmaceuticals, Inc.
The Income Pick
REGN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.51, yield 0.6%
- Rev growth 1.0%, EPS growth 8.2%, 3Y rev CAGR 5.6%
- Lower volatility, beta 0.51, Low D/E 8.7%, current ratio 4.13x
- 1.0% revenue growth vs IMVT's -22.2%
Best for: income & stability and growth exposure
OCUL
Ocular Therapeutix, Inc.
The Defensive Pick
OCUL is the clearest fit if your priority is defensive.
- Beta 1.25, current ratio 15.39x
Best for: defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  REGN | 1.0% revenue growth vs IMVT's -22.2% |
| Quality / Margins | REGN | 29.6% margin vs OCUL's -5.6% |
| Stability / Safety | REGN | Beta 0.51 vs AURA's 1.68, lower leverage |
| Dividends | REGN | 0.6% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) |  IMVT | +110.9% vs AURA's -3.9% |
| Efficiency (ROA) | REGN | 11.1% ROA vs AURA's -64.1%, ROIC 8.9% vs -72.4% |
AURA vs IMVT vs REGN vs OCUL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
AURA vs IMVT vs REGN vs OCUL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREGNLAGGINGOCUL
Who Leads Where
REGN leads in 3 of 6 categories
IMVT leads 1 • AURA leads 0 • OCUL leads 0 • 1 tied
Explore the data ↓OCULOcular Therapeutix, I…
0leads
AURAAura Biosciences, Inc.
0leads
IMVTImmunovant, Inc.
1leads
REGNRegeneron Pharmaceuti…
3leads
6 Total Categories
CATEGORYLEADERvs IMVTvs AURAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REGN4/6
Valuation MetricsMultiples, price ratios, and targets
REGN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REGN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
REGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN and IMVT operate at a comparable scale, with $14.9B and $0 in trailing revenue. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to OCUL's -5.6%. On growth, REGN holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  AURAAura Biosciences,… | IMVTImmunovant, Inc. | REGNRegeneron Pharmac… |  OCULOcular Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $14.9B | $52M |
| EBITDAEarnings before interest/tax | -$117M | -$532M | $4.2B | -$295M |
| Net IncomeAfter-tax profit | -$112M | -$506M | $4.4B | -$290M |
| Free Cash FlowCash after capex | -$92M | -$407M | $4.2B | -$241M |
| Gross MarginGross profit ÷ Revenue | — | — | +84.5% | +87.2% |
| Operating MarginEBIT ÷ Revenue | — | — | +24.3% | -5.8% |
| Net MarginNet income ÷ Revenue | — | — | +29.6% | -5.6% |
| FCF MarginFCF ÷ Revenue | — | — | +27.9% | -4.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +19.0% | +0.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.1% | -14.1% | -7.2% | -5.3% |
REGN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
REGN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | AURAAura Biosciences,… | IMVTImmunovant, Inc. | REGNRegeneron Pharmac… | OCULOcular Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $412M | $6.9B | $63.6B | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $369M | $6.0B | $63.2B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -3.64x | -12.14x | 14.76x | -6.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 13.18x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.33x | — |
| EV / EBITDAEnterprise value multiple | — | — | 15.33x | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 4.43x | 37.77x |
| Price / BookPrice ÷ Book value/share | 2.82x | 7.19x | 2.13x | 2.56x |
| Price / FCFMarket cap ÷ FCF | — | — | 15.59x | — |
REGN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
REGN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
REGN delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-78 for AURA. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to AURA's 0.13x. On the Piotroski fundamental quality scale (0–9), REGN scores 5/9 vs IMVT's 2/9, reflecting solid financial health.
| Metric | AURAAura Biosciences,… | IMVTImmunovant, Inc. | REGNRegeneron Pharmac… | OCULOcular Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -78.1% | -68.2% | +14.3% | -64.6% |
| ROA (TTM)Return on assets | -64.1% | -62.2% | +11.1% | -48.4% |
| ROICReturn on invested capital | -72.4% | — | +8.9% | — |
| ROCEReturn on capital employed | -70.8% | -68.3% | +10.2% | -46.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.13x | 0.00x | 0.09x | 0.12x |
| Net DebtTotal debt minus cash | -$42M | -$902M | -$412M | -$657M |
| Cash & Equiv.Liquid assets | $60M | $902M | $3.1B | $737M |
| Total DebtShort + long-term debt | $17M | $72,000 | $2.7B | $80M |
| Interest CoverageEBIT ÷ Interest expense | — | — | 108.44x | -24.63x |
REGN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $31,304 today (with dividends reinvested), compared to $4,331 for AURA. Over the past 12 months, IMVT leads with a +110.9% total return vs AURA's -3.9%. The 3-year compound annual growth rate (CAGR) favors IMVT at 15.7% vs AURA's -20.0% — a key indicator of consistent wealth creation.
| Metric | AURAAura Biosciences,… | IMVTImmunovant, Inc. | REGNRegeneron Pharmac… | OCULOcular Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +20.9% | +29.8% | -20.9% | -24.4% |
| 1-Year ReturnPast 12 months | -3.9% | +110.9% | +18.0% | -0.1% |
| 3-Year ReturnCumulative with dividends | -48.8% | +55.0% | -18.1% | +37.5% |
| 5-Year ReturnCumulative with dividends | -56.7% | +213.0% | +16.8% | -36.9% |
| 10-Year ReturnCumulative with dividends | -56.7% | +237.9% | +68.2% | +39.7% |
| CAGR (3Y)Annualised 3-year return | -20.0% | +15.7% | -6.4% | +11.2% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMVT and REGN each lead in 1 of 2 comparable metrics.
Risk & Volatility
REGN is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than AURA's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 92.7% from its 52-week high vs OCUL's 54.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AURAAura Biosciences,… | IMVTImmunovant, Inc. | REGNRegeneron Pharmac… | OCULOcular Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.66x | 0.51x | 1.25x |
| 52-Week HighHighest price in past year | $9.54 | $36.27 | $821.11 | $16.44 |
| 52-Week LowLowest price in past year | $4.73 | $14.32 | $503.25 | $6.23 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +92.7% | +74.6% | +54.4% |
| RSI (14)Momentum oscillator 0–100 | 29.7 | 57.9 | 37.5 | 49.7 |
| Avg Volume (50D)Average daily shares traded | 549K | 1.9M | 868K | 2.8M |
Evenly matched — IMVT and REGN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AURA as "Buy", IMVT as "Buy", REGN as "Buy", OCUL as "Buy". Consensus price targets imply 235.6% upside for OCUL (target: $30) vs 29.9% for IMVT (target: $44). REGN is the only dividend payer here at 0.56% yield — a key consideration for income-focused portfolios.
| Metric | AURAAura Biosciences,… | IMVTImmunovant, Inc. | REGNRegeneron Pharmac… | OCULOcular Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $43.67 | $836.00 | $30.00 |
| # AnalystsCovering analysts | 8 | 23 | 48 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.6% | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | $3.41 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +6.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
REGN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns). 1 tied.
Best OverallRegeneron Pharmaceuticals, … (REGN)Leads 3 of 6 categories
Loading custom metrics...
AURA vs IMVT vs REGN vs OCUL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AURA or IMVT or REGN or OCUL a better buy right now?
For growth investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Aura Biosciences, Inc. (AURA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AURA or IMVT or REGN or OCUL?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +213. 0%, compared to -56. 7% for Aura Biosciences, Inc. (AURA). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus AURA's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AURA or IMVT or REGN or OCUL?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.
(REGN) is the lower-risk stock at 0. 51β versus Aura Biosciences, Inc. 's 1. 68β — meaning AURA is approximately 232% more volatile than REGN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for Aura Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — AURA or IMVT or REGN or OCUL?
By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.
(REGN) is pulling ahead at 1. 0% versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AURA or IMVT or REGN or OCUL?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus -513. 2% for Ocular Therapeutix, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -521. 0% for OCUL. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AURA or IMVT or REGN or OCUL more undervalued right now?
Analyst consensus price targets imply the most upside for OCUL: 235.
6% to $30. 00.
07Which pays a better dividend — AURA or IMVT or REGN or OCUL?
In this comparison, REGN (0.
6% yield) pays a dividend. AURA, IMVT, OCUL do not pay a meaningful dividend and should not be held primarily for income.
08Is AURA or IMVT or REGN or OCUL better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), 0. 6% yield). Aura Biosciences, Inc. (AURA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +68. 2%, AURA: -56. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AURA and IMVT and REGN and OCUL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AURA is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; OCUL is a small-cap quality compounder stock. REGN pays a dividend while AURA, IMVT, OCUL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.